Bifidobacterium longum 35624 (Bifantis)
Bifidobacterium longum 35624 is a clinically studied probiotic strain that produces short-chain fatty acids and anti-inflammatory compounds. It modulates the gut-brain axis through vagal nerve signaling and immune regulation, particularly beneficial for IBS management.
Origin & History
Bifidobacterium longum 35624 is a specific strain of Bifidobacterium longum isolated from the human gut. It is cultivated under controlled conditions for use in supplements.
Historical & Cultural Context
Bifidobacteria have been a part of the human diet through fermented foods, playing a crucial role in maintaining digestive health across various cultures.
Health Benefits
- Alleviates IBS symptoms by 60% through balancing gut flora, leading to improved digestive comfort. - Enhances immune response by increasing IgA production, fortifying the body's defenses against infections. - Supports mental health by reducing cortisol levels, which can decrease stress and anxiety. - Promotes skin health by reducing eczema symptoms, leading to clearer, healthier skin. - Aids in weight management by modulating gut hormones, helping to control appetite and reduce fat storage. - Improves nutrient absorption by enhancing gut barrier function, ensuring efficient uptake of vitamins and minerals. - Reduces inflammation by modulating immune responses, which can alleviate symptoms of chronic inflammatory conditions.
How It Works
Bifidobacterium longum 35624 produces butyrate and acetate that strengthen intestinal barrier function and reduce pro-inflammatory cytokines like TNF-α and IL-6. The strain stimulates dendritic cells to increase secretory IgA production while modulating the hypothalamic-pituitary-adrenal axis through vagal nerve communication. It also produces GABA precursors that influence neurotransmitter balance and cortisol regulation.
Scientific Research
Clinical trials have demonstrated its effectiveness in reducing IBS symptoms and improving gut health. It is well-supported by scientific research for its gastrointestinal benefits.
Clinical Summary
A randomized controlled trial with 362 IBS patients showed Bifidobacterium longum 35624 reduced symptom severity by 60% over 4 weeks compared to placebo. The strain demonstrated significant improvements in abdominal pain, bloating, and bowel movement satisfaction scores. Additional studies indicate increased fecal IgA levels and reduced inflammatory markers, though most clinical evidence focuses on IBS-specific outcomes. Long-term safety data beyond 12 weeks remains limited.
Nutritional Profile
Bifidobacterium longum 35624 (Bifantis) is a probiotic strain, not a traditional food ingredient, so it does not contribute macronutrients (carbohydrates, fats, proteins) or micronutrients (vitamins, minerals) in meaningful dietary quantities. Key bioactive components include: Live bacterial cells typically delivered at 1×10^8 CFU (100 million colony-forming units) per dose in commercial formulations such as Align. The strain produces short-chain fatty acids (SCFAs) including acetate and lactate as metabolic byproducts during fermentation in the gut, which indirectly contribute to colonic energy metabolism (~1-2 mM acetate production in vitro). Cell wall components include lipoteichoic acids and exopolysaccharides, which are the primary immunomodulatory bioactive compounds responsible for TLR2/TLR4 receptor interactions. The strain produces no appreciable B-vitamins or fiber in supplement form. Bioavailability note: Survival through gastric transit is estimated at 20-40% of ingested CFUs reaching the colon intact, depending on formulation (enteric coating improves delivery). The strain is typically encapsulated with microcrystalline cellulose and magnesium stearate as excipients, contributing negligible nutritional value. No significant caloric contribution (~0-2 kcal per dose).
Preparation & Dosage
Typical dosages range from 1 to 10 billion CFUs per day. Consult a healthcare provider before use.
Synergy & Pairings
Prebiotics, Lactobacillus rhamnosus, Psyllium husk, Omega-3 fatty acids
Safety & Interactions
Bifidobacterium longum 35624 is generally well-tolerated with mild side effects including temporary bloating or gas during initial supplementation. No significant drug interactions have been reported, though immunocompromised individuals should consult healthcare providers before use. The strain may theoretically reduce effectiveness of antibiotics if taken simultaneously. Pregnancy and breastfeeding safety has not been established through clinical trials.